Evaxion A (EVAX) Research & Development (2020 - 2026)
Evaxion A (EVAX) posted Research & Development of -$2.3 million for Q1 2026, up 10.2% on a QoQ basis from -$2.6 million in Q4 2025, and down 6.59% year-over-year from -$2.5 million in Q1 2025.
Evaxion A (EVAX) Research & Development (2020 - 2026) Analysis & Trends
Evaxion A's Research & Development history runs 7 years deep, the most recent figure standing at -$2.3 million for Q1 2026.
- Quarterly Research & Development fell 6.59% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.1 million (down 3.45% YoY) and the FY2025 annual result came in at -$10.0 million, up 4.61% from the prior year.
- Research & Development was -$2.3 million for Q1 2026 at Evaxion A, up from -$2.6 million in the prior quarter.
- Across five years, Research & Development topped out at $4.8 million in Q1 2022 and bottomed at -$4.1 million in Q4 2022.
- A 5-year average of -$1.5 million and a median of -$2.6 million in 2025 frame the typical range for Research & Development.
- Peak annual rise in Research & Development reached 43.58% in 2023, while the deepest fall reached 180.18% in 2023.
- Evaxion A's Research & Development stood at -$4.1 million in 2022, then surged by 43.58% to -$2.3 million in 2023, then gained by 1.87% to -$2.3 million in 2024, then declined by 13.48% to -$2.6 million in 2025, then rose by 10.2% to -$2.3 million in 2026.
- Business Quant data shows EVAX's Research & Development at -$2.3 million in Q1 2026, -$2.6 million in Q4 2025, and -$3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Evaxion A | 1.23 Bn | 1.23 Bn | - | -2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.30 Mn |
| Dec 31, 2025 | -2.56 Mn |
| Sep 30, 2025 | -3.09 Mn |
| Jun 30, 2025 | -2.17 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Dec 31, 2024 | -2.26 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -2.84 Mn |
| Dec 31, 2023 | -2.30 Mn |
| Sep 30, 2023 | -2.83 Mn |
| Jun 30, 2023 | -2.94 Mn |
| Mar 31, 2023 | -3.85 Mn |
| Dec 31, 2022 | -4.07 Mn |
| Sep 30, 2022 | 4.07 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 4.80 Mn |
| Dec 31, 2021 | 6.15 Mn |
| Sep 30, 2021 | 13.43 Mn |
| Jun 30, 2021 | 9.00 Mn |